Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01961414

Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910 — RANGE  

Exudative Age-related Macular Degeneration Clinical Trial

Official title:
Treat and Extend Therapy Using Intravitreal Aflibercept (IAI) for Previously Treated Patients Exiting the Wet Age-related Macular Degeneration Extension Study (0910)

Clinical Trial Summary

The purpose of this research study is to determine if a "Treat and Extend" regimen (increasing the time between visits when the disease is stable and not getting worse) of aflibercept 2.0mg injections inside the eye for treating patients with Wet Age-related Macular Degeneration.

Clinical Trial Description

After exiting VGFT-OD 0910, patients will be enrolled into RANGE, a longterm extension trial evaluating the safety and efficacy of aflibercept IAI utilizing a "treat and extend" regimen. Using pre-specified re-treatment criteria, treatment intervals will be variable with dosing of the active treatment at least every 12 weeks. ;

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01961414
Study type Interventional
Source Palmetto Retina Center, LLC
Contact
Status Active, not recruiting
Phase Phase 4
Start date October 2013
Completion date July 2016
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01950741 - Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Phase 4
Recruiting NCT01608113 - Long-term Follow-up of Subfoveal Neovascular AMD N/A
Completed NCT01404845 - Macular Pigment Density Evolution in Unilateral Wet AMD Versus Non AMD Patients With or Without Lutein and Zeaxanthine Supplementation N/A
Completed NCT01213082 - ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD) Phase 1/Phase 2
Completed NCT01304693 - ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients Phase 1/Phase 2
Completed NCT01810042 - Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab Phase 4
Completed NCT04640272 - A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration Phase 2
Active, not recruiting NCT02976194 - Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy Phase 4
Completed NCT01500915 - FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration Phase 4
Enrolling by invitation NCT05539235 - Efficacy and Safety of Intravitreal Conbercept With Modified Treat-and-Extend Regimens in Exudative AMD Phase 2/Phase 3
Completed NCT02355028 - LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration Phase 2
Unknown status NCT02089503 - Monocentric Retrospective Observational Study on Patients With Macular Degeneration N/A
Completed NCT01796964 - Efficacy and Safety Study of ESBA1008 Versus EYLEA® Phase 2
Completed NCT01127360 - LUCAS (Lucentis Compared to Avastin Study) Phase 4
Terminated NCT02348359 - X-82 to Treat Age-related Macular Degeneration Phase 2
Recruiting NCT02328209 - Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration N/A
Completed NCT01849692 - ESBA1008 Microvolume Study Phase 2
Completed NCT01157065 - Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration Phase 2
Completed NCT04138420 - Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab
Completed NCT03744806 - Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD